Eli Lilly's Lawsuits Against Compounded Tirzepatide Sellers: Case Tracker

Released: November 9, 2026 · Last reviewed: November 9, 2026

Courts read in November 2026: which of Lilly’s suits against compounded-tirzepatide sellers survive, which failed, and what a patient should check.

Lilly filed most of these cases in April 2025, after tirzepatide left FDA's shortage list. Nineteen months later, none has reached trial. The rulings so far say less about whether compounded tirzepatide is legal than about who can sue, over which words, and in which court.

This tracker covers lawsuits by Lilly against telehealth platforms and compounding pharmacies, plus one countersuit and one advertising challenge. It does not cover FDA warning letters or the FTC's separate cases; see our FDA enforcement tracker for those.

Case tracker: Lilly v. compounded-tirzepatide sellers

What Lilly alleged, in four buckets

1. False advertising under the Lanham Act. This federal law lets a competitor sue over false statements about a product. Lilly used it in every telehealth case. The trouble has been standing: Lilly must show the ads, not something else, cost it sales.

2. "Personalized" claims. This is the theory that keeps surviving. Lilly says programs market tirzepatide as tailored to you while shipping the same few strengths to everyone. In the Henry Meds case, the judge let the "personalized" claims go forward and dismissed the "safe and effective" ones. The Fella order did the same, keeping only statements about "personalized treatment plans."

3. Unapproved new drug. In the Revive Rx case, Lilly sued under state unfair-competition laws, arguing that mass-producing a copy of an approved drug evades "new drug" rules. On August 4, 2026, the court refused to throw those claims out.

4. State unfair-competition and corporate-practice claims. Against Mochi, Lilly argues the company, not doctors, changed patients' doses and formulations for business reasons, which California bars. That claim survived in April 2026.

Why some cases failed

Three reasons recur in the orders.

• No proof of lost sales. Mochi's first complaint failed because Lilly had not shown injury. Lilly fixed that on its second try.
• The doctor breaks the chain. Willow's judge held that a prescription, not the ad, decides what a patient takes, writing that "the physician's prescribing decision, not Willow's advertisements, is the proximate cause." Empower's Lanham Act claim also failed on proximate cause.
• Wrong court. Strive's case was dismissed in Delaware because Lilly did not tie Strive's online ads to that state.

One more point matters for patients. In the Fella order, the judge treated most of Lilly's attacks on weight-loss percentages as complaints that the claims were unproven, which a competitor generally cannot sue over. That makes regulators such as the FTC the more likely check on results claims.

Which tracked programs are named

Two of the programs in our pricing database are defendants: Mochi Health and Henry Meds. None of the others we track, including NexLife, Eden, Ro, Hims or Hers, appears as a defendant in the cases we found.

• Mochi Health. On October 15, 2026, Mochi printed no compounded price on its weight-loss page; the page showed a $199 12-month membership option. On November 9, 2026, its compounded tirzepatide page read "$90 /mo + Mochi Membership" as a starting-dose price, saying "higher doses cost more," and its homepage put the membership at "$79/month" after a $0 first month for new subscribers.
• Henry Meds. On October 15, 2026, Henry's tirzepatide URL returned a 404 and its GLP-1 page gave only a "starts at" price. On November 9, 2026, its GLP-1 page printed no price we could read. Its status in our dataset stays "pending."

Neither company has been found liable. Every claim in the table is an allegation unless a court has ruled on it, and the rulings so far are about whether Lilly may proceed, not whether Lilly is right.

What this means for you

If your program is named, nothing in these orders stops your next shipment. The practical risk is change: a new formulation, a new pharmacy, or a price move while the company litigates. Here is what to check.

1. Your vial label. Lilly alleges Mochi changed doses or formulations in December 2024, March 2025 and September 2025, and that additives such as niacinamide, glycine or pyridoxine varied by pharmacy. Compare each new label with the last. If it changed, ask your prescriber why.
2. What "personalized" means for you. Ask what in your prescription was set for you: dose, schedule, or formula. The NAD said a doctor choosing among set strengths "does not mean the product itself is individually created."
3. The FDA status line. Compounded tirzepatide is not FDA-approved and is not a generic. It is made with the drug in Zepbound, not the same product. A page that implies otherwise is a warning sign. Our legality explainer covers why it can still be sold.
4. Prepaid terms. If a program had to stop selling, how would unshipped months be handled? Find that sentence before you prepay.
5. Your backup price. Know what the brand would cost you.

Worked examples, 12 months

Staying at Mochi's starting dose. Using the November 9 figures: $90 × 12 = $1,080 for medication, plus $79 × 11 = $869 for membership after the $0 first month. That is $1,949 for the year, and more if your dose rises.

Moving to another tracked program. NexLife's compounded tirzepatide is $129 month to month as of November 6, 2026, or $1,548 for 12 months; its 12-month plan is $115 a month, $1,380 a year. Eden Health listed $129 a month on October 15, 2026, the same as NexLife's month-to-month price, which is also $1,548 a year. Among these, the gap against Mochi's starting dose is $401 to $569 a year. Compare more programs on our reviews page.

Switching to brand Zepbound. Lilly's self-pay vials run $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5–15 mg if you refill within 45 days. At $449, a year costs $5,388. Miss the refill window and 10–15 mg rises to $699, or $8,388 a year. Details are in our Zepbound cost guide.

On Medicare. For tirzepatide, the Medicare GLP-1 Bridge covers only the Zepbound KwikPen, not vials (it also covers Wegovy and Foundayo), at a $50 copay from July 1, 2026 to December 31, 2027. Twelve fills cost $600. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.

Results differ by drug and dose. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand); in SURMOUNT-5, tirzepatide averaged 20.2% versus 13.7% for semaglutide. Those trials used Lilly's product. They do not promise any result from a compounded version.

What to watch next

• Mochi: a case management conference was held on November 4, 2026, with the parties asked to address private mediation; we have not seen the outcome.
• Henry Meds: the court-ordered document production is due November 20, 2026.
• Willow: a Ninth Circuit ruling would bind the California federal courts where the Mochi, Henry Meds and Fella cases are pending.

We update this tracker when a new order posts. Recent changes appear on our news page, and our verification methodology explains how we date and source each price.

Frequently asked questions

Has Eli Lilly sued compounded tirzepatide sellers?

Yes: since 2023, and mostly in April 2025, Eli Lilly has sued telehealth sellers and compounding pharmacies, including Mochi Health, Henry Meds, Fella, Willow, Empower and Strive, mostly over advertising claims such as "personalized" tirzepatide, and by November 2026 some claims were dismissed while others survived into discovery. No order we read bars compounded tirzepatide outright or finds Mochi or Henry Meds liable. If your program is named, check your vial label and refund terms, and talk to your prescriber before switching. The case tracker lists every order we read, with dates.

Has a court ruled that compounded tirzepatide is illegal?

No. None of the orders we read decides whether compounded tirzepatide may be sold. They decide whether Lilly has standing, whether specific ad claims can be challenged, and whether the court has jurisdiction. The surviving claims mostly target marketing words such as "personalized," not the drug itself. Compounded tirzepatide is still not FDA-approved, and FDA rules on copies of approved drugs apply separately from these lawsuits.

Is my Mochi Health or Henry Meds prescription affected?

Not by any order we read. No court has barred either company from prescribing or shipping. Both cases are in discovery, and neither company has been found liable. What can change is the product or price, so check each vial label against the last one and reread your plan's refund terms. Mochi's starting-dose price on November 9, 2026 was $90 a month plus membership.

Why were the Willow Health and Strive cases dismissed?

For different reasons. Willow's judge held that a doctor's prescription, not Willow's ads, decides what a patient takes, so Lilly could not show the ads caused lost sales. The amended complaint was dismissed with prejudice on February 3, 2026. Strive's case was dismissed on October 8, 2025 because Lilly sued in Delaware without tying Strive's ads to that state.

Why does the word "personalized" matter so much?

It is the claim courts keep letting Lilly pursue. Judges in the Henry Meds and Fella cases found that whether a company actually personalizes treatment can be proven true or false. Lilly says programs ship the same few strengths to everyone while advertising tailored medicine. In November 2026, the NAD reached a similar view about one seller's "personalized" claims.

What should I do if my formulation changes or shipments stop?

Do not stop or switch medication on your own. Ask your prescriber why the formula changed and whether your dose should change with it. If shipments stop, ask in writing how unshipped prepaid months will be refunded. Then price your options: a compounded program, brand Zepbound at $299 to $449 a month with on-time refills, or the Medicare Bridge's $50 copay if you qualify.

Sources

1. Eli Lilly v. Mochi Health Corp., Order re Motion to Dismiss (Dkt. 95) (U.S. District Court, N.D. Cal., October 24, 2025; read November 2026)
2. Eli Lilly v. Mochi Health Corp., Order re Motion to Dismiss First Amended Complaint (Dkt. 126) (U.S. District Court, N.D. Cal., April 20, 2026; read November 2026)
3. Eli Lilly v. Mochi Health Corp., Pretrial Order No. 1: Case Schedule (Dkt. 132) (U.S. District Court, N.D. Cal., May 21, 2026; read November 2026)
4. Eli Lilly v. Mochi Health Corp., Order re Motion to Dismiss Second Amended Complaint (Dkt. 146) (U.S. District Court, N.D. Cal., September 8, 2026; read November 2026)
5. Eli Lilly v. Adonis Health (Henry Meds), Order Granting in Part and Denying in Part Motion to Dismiss (ECF 62) (U.S. District Court, N.D. Cal., September 24, 2025; read November 2026)
6. Eli Lilly v. Adonis Health (Henry Meds), Discovery Order (ECF 112) (U.S. District Court, N.D. Cal., October 14, 2026; read November 2026)
7. Eli Lilly v. Aios Inc. (Fella Health and Delilah), Order Granting in Part and Denying in Part Motion to Dismiss (Dkt. 88) (U.S. District Court, N.D. Cal., March 26, 2026; read November 2026)
8. Eli Lilly v. Willow Health Services, Order Granting Motion to Dismiss First Amended Complaint (Dkt. 71) (U.S. District Court, C.D. Cal., February 3, 2026, copy hosted by the Alliance for Pharmacy Compounding; read November 2026)
9. Eli Lilly v. Empower Clinic Services, Memorandum Opinion and Order (Dkt. 80) (U.S. District Court, S.D. Tex., April 29, 2026; read November 2026)
10. Eli Lilly v. Strive Pharmacy, Memorandum Opinion (D.I. 21) (U.S. District Court, D. Del., October 8, 2025; read November 2026)
11. Eli Lilly v. Revive Rx, Memorandum and Opinion (Dkt. 155) (U.S. District Court, S.D. Tex., August 4, 2026; read November 2026)
12. Strive Specialties v. Eli Lilly, Opinion and Order on Reconsideration (Dkt. 61) (U.S. District Court, W.D. Tex., October 20, 2026; read November 2026)
13. NAD Case #7586: Good Life Meds, LLC (BBB National Programs, November 4, 2026; read November 2026)
14. Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro (CNBC, April 23, 2025; read November 2026)
15. Eli Lilly sues Strive and Empower over compounded tirzepatide (CNBC, April 1, 2025; read November 2026)
16. Compounded Tirzepatide (Mochi Health, undated page; read November 2026)